U.S. Leisure Stock News

FTI Consulting (NYSE:FCN) has expanded its Corporate Finance & Restructuring segment with senior hires in aviation, healthcare and transaction advisory. Scott Davidson has been appointed to lead Aviation Business Transformation, focusing on aviation clients in international markets. Oussama Nicolas and Tara Makarem have been named to lead a new healthcare and life sciences offering in the Middle East. Mustapha Labassi has joined the Paris office to strengthen Transaction Services across...

UiPath recently announced new agentic AI solutions for healthcare at the ViVE 2026 conference in Los Angeles, including tools for medical records summarization, claim denial prevention, and prior authorization to support revenue cycle management. By embedding healthcare domain expertise through partners such as Genzeon, UiPath is aiming to reduce administrative workloads for providers and tie its automation platform more directly to patient-care and financial outcomes. We’ll now examine how...

Solventum stock snapshot after recent performance trends Solventum (SOLV) has caught investor attention after recent share price weakness, with the stock showing negative returns over the past week, month, and past 3 months while still posting modest annual revenue and net income growth. See our latest analysis for Solventum. The recent weakness, including a 7.57% 1 month share price decline and a 12.52% 3 month share price decline from a latest share price of $72.94, contrasts with a...

Why Kennedy-Wilson Holdings (KW) is on investors’ radar today Kennedy-Wilson Holdings (KW) has drawn attention after recent share price moves, with the stock showing double digit total returns over the past year, while longer term performance has been weaker. See our latest analysis for Kennedy-Wilson Holdings. Recent trading has been firm, with a 7 day share price return of 10.21% and a 90 day share price return of 13.31%, while the 1 year total shareholder return of 29.97% contrasts with...

In February 2026, Microchip Technology expanded its edge AI offering into full-stack MCU and MPU platforms, announced an US$800 million zero-coupon senior unsecured convertible note due 2030, and participated in multiple semiconductor conferences, including the Chiplet Summit 2026 and Wolfe Research’s Auto, Auto Tech and Semiconductor Conference. The push into turnkey edge AI solutions, combining silicon, software, tools and pre-trained models, signals Microchip’s intent to move closer to...

Tariff reset puts Best Buy (BBY) back in the spotlight A fresh 15% U.S. tariff announcement, following a Supreme Court ruling that curtailed earlier levies, has put Best Buy (BBY) on investors’ radar as a potential beneficiary if duties are later rolled back. See our latest analysis for Best Buy. Tariff headlines are landing at a time when Best Buy’s share price has been under pressure, with a 90 day share price return of a 14.73% decline and a 1 year total shareholder return of a 24.32%...

Baidu (NasdaqGS:BIDU) and Uber are partnering to launch the Apollo Go autonomous ride hailing service in Dubai. The project represents Baidu's first large scale overseas deployment of its autonomous driving technology. Dubai plans to expand autonomous transportation by 2030, and this service is intended to support that city wide goal. The Dubai operation will be Baidu's first Apollo Go hub outside of China. For you as an investor looking at NasdaqGS:BIDU, this move places Baidu's core...

Gartner (NYSE:IT) is under investigation by a law firm following its fourth quarter financial results. The inquiry focuses on potential securities fraud or unlawful practices linked to the company’s recent disclosures. Gartner’s 2026 outlook missed expectations, prompting fresh scrutiny of management and investor communications. The investigation and earnings update are viewed as material for current and prospective shareholders. Gartner is a research and advisory firm that sells market...

Veeva Systems (VEEV) is back in focus after recent trading left the stock about 18% lower over the past month and roughly 24% lower over the past 3 months, prompting fresh questions about its valuation. See our latest analysis for Veeva Systems. At a latest share price of $180.31, Veeva Systems has seen its short term momentum cool, with a 30 day share price return of 18.78% and a 90 day share price return of 23.51%. The 3 year total shareholder return of 9.21% contrasts with a 1 year total...

In early February 2026, Graphic Packaging Holding reported weaker guidance, including an expected decline in 2026 Adjusted EBITDA, and soon after became the subject of a Pomerantz LLP investigation into potential securities law violations. These developments coincided with Atlantic Investment Management exiting its position, flat unit sales, earnings pressure, and David Einhorn significantly expanding his stake in the company. Together, the softer outlook, legal scrutiny, and contrasting...

Recent performance snapshot Upbound Group (UPBD) has caught investor attention after recent share price moves, with the stock last closing at US$22.78 and showing mixed return patterns over the past year and beyond. See our latest analysis for Upbound Group. The recent 12.2% 7 day and 18.1% 30 day share price returns suggest short term momentum is building, even though the 1 year total shareholder return of 7.6% points to a weaker longer term picture. If this move has you thinking about what...

If you are looking at Sonoco Products and wondering whether the current share price offers good value, this article will walk through what the numbers are really saying about the stock. The shares most recently closed at US$56.45, with returns of 9.3% over 7 days, 16.2% over 30 days, 27.2% year to date, 26.4% over 1 year, 7.2% over 3 years and 12.8% over 5 years. This helps frame how the market has been reassessing the company over different time frames. Recent coverage of Sonoco Products...

If you are wondering whether Dynex Capital's current share price offers good value, you are not alone, especially with income focused investors often watching mortgage REITs closely. The stock last closed at US$14.13, with returns of 0.6% over 7 days, a 3.4% decline over 30 days, 0.4% year to date, 17.4% over 1 year, 59.2% over 3 years and 35.7% over 5 years. This raises fair questions about how that performance lines up with the underlying value. Recent coverage around Dynex Capital has...

Why GATX’s latest earnings and capital moves matter for shareholders GATX (GATX) just posted double digit earnings growth for 2025, completed its large Wells Fargo railcar acquisition, and paired those results with higher dividends and a fresh $300 million buyback authorization. See our latest analysis for GATX. The recent rally has been strong, with a 1 day share price return of 5.0% and a 90 day share price return of 24.53% lifting GATX to US$198.52. The 5 year total shareholder return of...

In recent days, ACADIA Pharmaceuticals drew fresh attention after Wall Street analysts reacted to updates on its neurology and rare‑disease pipeline, highlighting the company’s transition from a single‑product focus to a broader portfolio with additional development‑stage and deal‑driven assets. This shift toward a more diversified set of neurology and genetic disorder programs has become a key talking point among analysts assessing how ACADIA balances Nuplazid’s importance with new...

If you are looking at Cytokinetics and wondering whether the current share price actually reflects its underlying value, you are not alone. The stock most recently closed at US$67.94, with returns of 2.5% over 7 days, 7.1% over 30 days, 10.1% year to date and 41.1% over the past year, which naturally raises questions about what is already priced in and what is not. Recent attention around Cytokinetics has focused on its pipeline progress and regulatory milestones, which often influence how...

Wondering whether Trane Technologies at around US$467 a share lines up with its underlying value, or if expectations have already run ahead of the story. The stock has posted returns of 0.4% over the last 7 days, 20.9% over the last 30 days, 17.4% year to date, 36.0% over 1 year and 214.8% over 5 years, which naturally raises questions about how much future upside or downside is now priced in. Recent news flow around Trane has highlighted ongoing attention on building efficiency and climate...

In February 2026, Trex Company expanded its Performance-Engineered outdoor living portfolio with cooler-running SunCom comfortable decking, new Transcend Lineage 1"x4" boards, enhanced railing options, and composite fencing, while appointing industry veteran Irene Tasi to its Board and Audit and Compensation Committees. Alongside these product launches and governance changes, Trex’s recent industry awards and sustainability rankings highlight a brand pushing innovation even as competitive...

Savara Inc. recently announced that the FDA has accepted for review its Biologics License Application for MOLBREEVI to treat autoimmune pulmonary alveolar proteinosis, granting Priority Review with a PDUFA action date of August 22, 2026. This filing caps a series of expedited and rare-disease designations across the US, EU and UK, underscoring MOLBREEVI’s potential importance for a severely underserved patient population. We’ll now examine how FDA Priority Review for MOLBREEVI, alongside its...

Mattel (MAT) has given investors a lot to digest in February, pairing a new US$1.5b share repurchase authorization with detailed 2026 product reveals and fresh earnings and sales guidance. See our latest analysis for Mattel. Despite the new product slate and the US$1.5b buyback authorization, Mattel’s recent share price return has been weak, with a 30 day share price return of 15.77% and a 1 year total shareholder return of 17.84%. This suggests momentum has been fading even as management...

ORIC Pharmaceuticals (NasdaqGS:ORIC) reports progress in its cancer therapy pipeline, with lead drug candidates entering Phase 1b clinical trials. The company announces new collaborations with Pfizer, Bayer, and Johnson & Johnson, aimed at advancing therapies that target resistance mechanisms in cancer treatment. These developments are drawing increased investor attention as they represent material steps in ORIC Pharmaceuticals' clinical and partnership strategy. ORIC Pharmaceuticals...

Rosen Law Firm announced that the U.S. District Court for the Southern District of New York has certified a class action and is reviewing a proposed US$740,000,000 settlement to resolve claims by DiDi Global ADS purchasers, with a hearing scheduled for June 16, 2026. If approved, this sizable settlement would cap a major legal overhang for DiDi Global, clarifying potential liabilities and closing a lengthy litigation chapter. Next, we will examine how this proposed US$740,000,000 class...

What Restaurant Brands International’s Recent Trading Tells You Restaurant Brands International (QSR) has drawn investor interest after a modest 0.3% gain in the latest session, adding to a 4.1% move over the past week and contrasting with a slight past 3 months pullback. See our latest analysis for Restaurant Brands International. At a share price of $68.82, Restaurant Brands International’s recent 7 day share price return of 4.05% sits against a quieter year to date move. However, a 1 year...

Equifax (EFX) has drawn fresh attention after launching Optimal Path, an AI driven credit score planner offered free inside the myEquifax mobile app, putting its data and analytics capabilities directly in front of U.S. consumers. See our latest analysis for Equifax. Equifax shares trade at US$197.46, with a 1 day share price return of 1.11% and a 7 day return of 2.42%. However, a 1 year total shareholder return decline of 16.52% suggests recent momentum has faded despite product launches...